MABT1551
Anti-Filaggrin Antibody, clone AHF7
Synonym(s):
FLG
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.43
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
AHF7, monoclonal
mol wt
observed mol wt ~N/A kDa
purified by
ion-exchange chromatography
species reactivity
human
packaging
antibody small pack of 100
technique(s)
ELISA: suitable
electron microscopy: suitable
immunofluorescence: suitable
immunohistochemistry: suitable
western blot: suitable
isotype
IgG1κ
epitope sequence
Unknown
Protein ID accession no.
UniProt accession no.
storage temp.
-10 to -25°C
Gene Information
human ... FLG(2312)
Specificity
Clone AHF7 is a mouse monoclonal antibody that detects the mature form of Filaggrin.
Immunogen
Partially purified Filaggrin from human breast skin tissue.
Application
Quality Control Testing
Evaluated by Immunohistochemistry (Paraffin) in Human skin tissue sections.
Immunohistochemistry (Paraffin) Analysis: A 1:50 dilution of this antibody detected Filaggrin in Human skin tissue sections.
Tested Applications
Immunohistochemistry Applications: A representative lot detected Filaggrin in Immunohistochemistry application. (Simon, M., et al. (1995). Clin Exp Immunol. 100(1):90-8; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56; Guy, R., et al. (1998). Dermatology. 196(1):32-7; Guy, R., et al. (1998). J Invest Dermatol. 110(4):410-5; Downie, M.M.T., et al. (2002). Br J Dermatol. 147(5):869-78; Chavanas, S., et al. (2006). J Dermatol Sci. 44(2):63-72).
Immunofluorescence Analysis: A representative lot detected Filaggrin in Immunfluorescence application. (Simon, M., et al. (1995). Clin Exp Immunol. 100(1):90-8; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56; Chavanas, S., et al. (2006). J Dermatol Sci. 44(2):63-72).
ELISA Analysis: A representative lot detected Filaggrin in ELISA application. (Simon, M., et al. (1996). Biochem J. 317(Pt1)(Pt1):173-7).
Electron Microscopy: A representative lot detected Filaggrin in Electron Microscopy application. (Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7).
Western Blotting Analysis: A representative lot detected Filaggrin in Western Blotting application. (Sebbag, M., et al. (1995). J Clin Invest. 95(6):2672-9; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Simon, M., et al. (1996). Biochem J. 317(Pt1)(Pt1):173-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56).
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Evaluated by Immunohistochemistry (Paraffin) in Human skin tissue sections.
Immunohistochemistry (Paraffin) Analysis: A 1:50 dilution of this antibody detected Filaggrin in Human skin tissue sections.
Tested Applications
Immunohistochemistry Applications: A representative lot detected Filaggrin in Immunohistochemistry application. (Simon, M., et al. (1995). Clin Exp Immunol. 100(1):90-8; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56; Guy, R., et al. (1998). Dermatology. 196(1):32-7; Guy, R., et al. (1998). J Invest Dermatol. 110(4):410-5; Downie, M.M.T., et al. (2002). Br J Dermatol. 147(5):869-78; Chavanas, S., et al. (2006). J Dermatol Sci. 44(2):63-72).
Immunofluorescence Analysis: A representative lot detected Filaggrin in Immunfluorescence application. (Simon, M., et al. (1995). Clin Exp Immunol. 100(1):90-8; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56; Chavanas, S., et al. (2006). J Dermatol Sci. 44(2):63-72).
ELISA Analysis: A representative lot detected Filaggrin in ELISA application. (Simon, M., et al. (1996). Biochem J. 317(Pt1)(Pt1):173-7).
Electron Microscopy: A representative lot detected Filaggrin in Electron Microscopy application. (Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7).
Western Blotting Analysis: A representative lot detected Filaggrin in Western Blotting application. (Sebbag, M., et al. (1995). J Clin Invest. 95(6):2672-9; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Simon, M., et al. (1996). Biochem J. 317(Pt1)(Pt1):173-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56).
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Filaggrin (UniProt: P20930; also known as FLG) is encoded by the FLG gene (Gene ID: 2312) in human. Filaggrin, a calcium-binding protein, is synthesized as a large, insoluble, highly phosphorylated precursor with several tandem copies of 324 amino acids in cytoplasmic granules. During terminal differentiation it undergoes dephosphorylation and proteolytic cleavage to remove linker peptides and produce functional basic filaggrin units. It is widely expressed and in skin tissue it is detected mainly in stratum granulosum of the epidermis. During terminal differentiation of mammalian epidermis, it aggregates keratin intermediate filaments and promotes disulfide-bond formation among the intermediate filaments. This creates the intracellular fibrous matrix of the cornified cells. Deimination of arginine to citrulline by peptidylarginine deiminase is reported to result in reduction in its affinity for cytokeratins. The N-terminal region of the mature filaggrin is shown to be heterogenous and is blocked by the formation of pyroglutamate. Clone AHF7 detects only the mature form of filaggrin and does not detect profilaggrin. It exhibits reactivity in various immunochemical applications. (Ref.: Simon, M., et al. (1996). Biochem. J. 317(pt 1); 173 177; Simon, M., et al. (1995). Clin. Exp. Immunol. 100(1); 90-98; Simon, M., et al. (1995). J. Invest. Dermatol. 105(3); 432-437).
Physical form
Purified mouse monoclonal antibody IgG1 in buffer containing PBS with 0.1% sodium azide with 50% glycerol.
Reconstitution
0.5 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Store at -10°C to -25°C. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service